Medical officer
Centers for Disease Control and Prevention
Atlanta, GA, United States
Fiona Havers, MD, MHS, FIDSA, is a Medical Officer and the Team Lead for the RESP-NET Surveillance Team in the Coronavirus and Other Respiratory Viruses Division within the U.S. CDC's National Center for Immunization and Respiratory Diseases (NCIRD). Dr. Havers is the CDC COVID-19 and RSV lead for RESP-NET, a population-based surveillance platforms that collect data on COVID-19, RSV, and influenza-associated hospitalizations.
Dr. Havers earned a Doctor of Medicine from the University of Washington. She completed training in internal medicine and infectious diseases at the Johns Hopkins University. She also obtained a Master’s of Health Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health and completed the Epidemic Intelligence Service training in the Influenza Division at CDC. She is board certified to practice internal medicine and infectious diseases and is a staff physician at the Atlanta VA Medical Center and an Adjunct Associate Professor in the Emory University Division of Infectious Diseases.
While at CDC, Dr. Havers’ research interests have focused on the epidemiology, prevention, and treatment of vaccine-preventable respiratory diseases, including influenza, pertussis, RSV and SARS-CoV-2. At the start of the COVID-19 pandemic, she led the establishment of large-scale seroprevalence studies before shifting focus to the epidemiology of COVID-19 and RSV-associated hospitalizations. She was previously pertussis vaccine policy lead in the Division of Bacterial Diseases, and prior to that, spent more than 5 years in the Influenza Division with research focused on influenza antiviral treatment, vaccine effectiveness and novel influenza viruses. Dr. Havers is also a captain in the US Public Health Service.
Disclosure(s): No financial relationships to disclose
112 - A Whole New World? Respiratory Syncytial Virus in the Vaccine and Monoclonal Antibody Era
Friday, October 18, 2024
10:30 AM – 11:45 AM US PT
264 - RSV in adults: Epidemiology of severe RSV disease and RSV vaccines in the first year
Friday, October 18, 2024
10:55 AM – 11:20 AM US PT